TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Ascentage Pharma
Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA

Ascentage Pharma received FDA and EMA clearance to conduct a global Phase III study of olverembatinib for treating newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), with promising early data showing high minimal residual disease negativity rates.

Insights
MSFT   negative

Disappointed investors with recent quarterly results


AAPG   positive

Company advancing promising cancer treatment with global regulatory approvals and potential breakthrough therapy for Ph+ ALL